Quick Answer
Apimeds Pharmaceuticals US, Inc. reported Cash and Equivalents of $3.5 thousand for fiscal year 2024.
Apimeds Pharmaceuticals US, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $3.5K | -99.2% |
| 2023 | $410.5K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.99M | — | -20.0% |
| June 30, 2025 | $8.74M | — | +3389.4% |
| March 31, 2025 | $250.3K | — | +7145.8% |
| December 31, 2024 | $3.5K | — | — |
- Apimeds Pharmaceuticals US, Inc. showed a decrease of -99.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2024 period, Apimeds Pharmaceuticals US, Inc.’s cash and equivalents has declined by 99.2% (from $410.5 thousand to $3.5 thousand).
- The most recent figure is from Apimeds Pharmaceuticals US, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: